206645-99-0
基本信息
坎普他汀, >98%
COMPSTATIN游离态
Compstatin,ICVVQDWGHHRCT, >98%
H-Ile-Cys-Val-Val-Gln-Asp-Trp-Gly-His-His-Arg-Cys-Thr-NH2
H-Ile-Cys-Val-Val-Gln-Asp-Trp-Gly-His-His-Arg-Cys-Thr-NH2, (Disulfide bond)
Compstatin trifluoroacetate salt H-Ile-Cys-Val-Val-Gln-Asp-Trp-Gly-His-His-Arg-Cys-Thr-NH2 trifluoroacetate salt (Disulfide bond)
L-Threoninamide, L-isoleucyl-L-cysteinyl-L-valyl-L-valyl-L-glutaminyl-L-α-aspartyl-L-tryptophylglycyl-L-histidyl-L-histidyl-L-arginyl-L-cysteinyl-, cyclic (2→12)-disulfide
物理化学性质
| 密度 | 1.56±0.1 g/cm3(Predicted) |
| 储存条件 | Keep in dark place,Inert atmosphere,Store in freezer, under -20°C |
| 酸度系数(pKa) | 4.00±0.10(Predicted) |
| 形态 | Solid |
| 颜色 | White to off-white |
| 水溶解性 | Soluble to 2 mg/ml in sterile water |
| 序列 | H-Ile-Cys-Val-Val-Gln-Asp-Trp-Gly-His-His-Arg-Cys-Thr-NH2(Disulfide bridge: Cys2-Cys11) |
应用领域
纯度(HPLC) ≥98.0%
醋酸根含量≤12.0%
水分含量≤8.0%
肽含量≥80.0%
内毒素≤50EU/mg
氨基酸组成分析≤±10%
COMPSTATIN价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2026/09/15 | HY-P1036 | COMPSTATIN Compstatin | 206645-99-0 | 500μg | 650元 |
| 2026/09/15 | HY-P1036 | COMPSTATIN Compstatin | 206645-99-0 | 1mg | 900元 |
| 2026/09/15 | HY-P1036 | COMPSTATIN Compstatin | 206645-99-0 | 5mg | 1800元 |
常见问题列表
Compstatin exhibits an in vitro half-life in human blood of about2 hr.
In solution, compstatin forms a β-turn at residues Gln-5–Gly-8 with the disulfide bridge Cys-2–Cys12, residues Ile-1–Val-4, and Thr-13, forming a hydrophobic cluster.
Compstatin (21 mg/kg) produces complete inhibition when given as a combination of bolus injection and infusion. Compstatin completely inhibits in vivo heparin/protamine-induced complement activation without adverse effects on heart rate or systemic arterial, central venous, and pulmonary arterial pressures.
Compstatin is stable in baboon plasma for more than 24 h.
Pig xenografts survival is significantly longer in the Compstatin perfused group than in the control group.
| Animal Model: | Juvenile baboons ( P. Anubis ) weighing 10.5-28.8 kg. |
| Dosage: | 50, 25 mg/kg 60 min after heparin and 2 min before protamine. |
| Administration: | A bolus injection. |
| Result: | Completely inhibited complement activation induced by heparin–protamine complexes. |